Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5825218 | 0.86 | USP2 (0.50) | USP2ALDH1A1KDM4ETSHRGLA | |
| SCHEMBL15187311 | 0.83 | USP2 (0.47) | USP2ALDH1A1KDM4ETSHRGLA | |
| SCHEMBL15187251 | 0.83 | USP2 (0.47) | USP2ALDH1A1KDM4ETSHRGLA | |
| SCHEMBL734049 | 0.82 | USP2 (0.72) | USP2ALDH1A1KDM4ETSHRGLA | |
| SCHEMBL12349244 | 0.82 | USP2 (0.54) | USP2ALDH1A1KDM4ETSHRGLA | |
| SCHEMBL15314029 | 0.81 | MEN1 (0.44) | ALDH1A1KDM4E | |
| SCHEMBL25299334 | 0.81 | USP2 (0.52) | USP2ALDH1A1KDM4ETSHRGLA | |
| SCHEMBL1453895 | 0.81 | USP2 (0.52) | USP2ALDH1A1KDM4ETSHRGLA | |
| SCHEMBL9729323 | 0.80 | USP2 (0.52) | USP2ALDH1A1KDM4ETSHRGLA | |
| SCHEMBL22539919 | 0.79 | USP2 (0.47) | USP2ALDH1A1KDM4EGLASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170348320-A1 | IMIDAZOLOTHIAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASE | AMBIT BIOSCIENCES CORP (US) | 2017-12-07 | — | — | US | disclosed |
| US-20150126505-A1 | IMIDAZOLOTHIAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASE | AMBIT BIOSCIENCES CORP (US) | 2015-05-07 | — | — | US | disclosed |
| US-8921546-B2 | Imidazolothiazole compounds for the treatment of disease | AMBIT BIOSCIENCES CORPORATION (US) | 2014-12-30 | — | — | US | disclosed |
| US-20140243525-A1 | IMIDAZOLOTHIAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASE | AMBIT BIOSCIENCES CORPORATION (US) | 2014-08-28 | — | — | US | disclosed |
| US-8557810-B2 | Imidazolothiazole compounds for the treatment of disease | AMBIT BIOSCIENCES CORPORATION (US) | 2013-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150126505-A1 | IMIDAZOLOTHIAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASE | GRK2, GRK4, GRK3 | USP2 2802/4885ALDH1A1 3704/4885KDM4E 4443/4885 |
| US-20140243525-A1 | IMIDAZOLOTHIAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASE | GRK2, GRK4, GRK3 | USP2 2802/4885ALDH1A1 3704/4885KDM4E 4443/4885 |
| US-20170348320-A1 | IMIDAZOLOTHIAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASE | GRK2, GRK4, GRK3 | USP2 2802/4885ALDH1A1 3704/4885KDM4E 4443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.